nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—trigeminal nerve—bone cancer	0.214	0.511	CbGeAlD
Fosaprepitant—TACR1—cranial nerve—bone cancer	0.153	0.364	CbGeAlD
Fosaprepitant—TACR1—connective tissue—bone cancer	0.0315	0.0751	CbGeAlD
Fosaprepitant—Aprepitant—CYP3A4—bone cancer	0.0248	1	CrCbGaD
Fosaprepitant—TACR1—spinal cord—bone cancer	0.0209	0.0498	CbGeAlD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00204	0.00367	CcSEcCtD
Fosaprepitant—Hot flush—Doxorubicin—bone cancer	0.00203	0.00366	CcSEcCtD
Fosaprepitant—Discomfort—Cisplatin—bone cancer	0.00203	0.00365	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Doxorubicin—bone cancer	0.00201	0.00363	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00198	0.00356	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Cisplatin—bone cancer	0.00197	0.00354	CcSEcCtD
Fosaprepitant—Oedema—Cisplatin—bone cancer	0.00197	0.00354	CcSEcCtD
Fosaprepitant—Infection—Cisplatin—bone cancer	0.00195	0.00352	CcSEcCtD
Fosaprepitant—Lethargy—Doxorubicin—bone cancer	0.00194	0.00349	CcSEcCtD
Fosaprepitant—Nervous system disorder—Cisplatin—bone cancer	0.00193	0.00347	CcSEcCtD
Fosaprepitant—Skin disorder—Cisplatin—bone cancer	0.00191	0.00344	CcSEcCtD
Fosaprepitant—Hyponatraemia—Doxorubicin—bone cancer	0.00191	0.00343	CcSEcCtD
Fosaprepitant—Osteoarthritis—Doxorubicin—bone cancer	0.0019	0.00342	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Cisplatin—bone cancer	0.0019	0.00342	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Epirubicin—bone cancer	0.00188	0.00338	CcSEcCtD
Fosaprepitant—Hypokalaemia—Epirubicin—bone cancer	0.00187	0.00336	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00185	0.00333	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00185	0.00333	CcSEcCtD
Fosaprepitant—Hypotension—Cisplatin—bone cancer	0.00184	0.00331	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—bone cancer	0.00182	0.00327	CcSEcCtD
Fosaprepitant—Muscular weakness—Epirubicin—bone cancer	0.00181	0.00326	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00181	0.00326	CcSEcCtD
Fosaprepitant—Abdominal distension—Epirubicin—bone cancer	0.00179	0.00322	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—bone cancer	0.00177	0.00319	CcSEcCtD
Fosaprepitant—Dyspnoea—Cisplatin—bone cancer	0.00175	0.00315	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Doxorubicin—bone cancer	0.00174	0.00312	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—bone cancer	0.00173	0.00312	CcSEcCtD
Fosaprepitant—Hypokalaemia—Doxorubicin—bone cancer	0.00173	0.00311	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00171	0.00308	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00171	0.00308	CcSEcCtD
Fosaprepitant—Decreased appetite—Cisplatin—bone cancer	0.00171	0.00308	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Cisplatin—bone cancer	0.0017	0.00305	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—bone cancer	0.00169	0.00304	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—bone cancer	0.00169	0.00304	CcSEcCtD
Fosaprepitant—Pain—Cisplatin—bone cancer	0.00168	0.00303	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00168	0.00302	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00168	0.00302	CcSEcCtD
Fosaprepitant—Muscular weakness—Doxorubicin—bone cancer	0.00168	0.00302	CcSEcCtD
Fosaprepitant—Dysuria—Epirubicin—bone cancer	0.00166	0.00299	CcSEcCtD
Fosaprepitant—Abdominal distension—Doxorubicin—bone cancer	0.00165	0.00298	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—bone cancer	0.00165	0.00297	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—bone cancer	0.00164	0.00296	CcSEcCtD
Fosaprepitant—Pollakiuria—Epirubicin—bone cancer	0.00164	0.00295	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Epirubicin—bone cancer	0.00162	0.00292	CcSEcCtD
Fosaprepitant—Feeling abnormal—Cisplatin—bone cancer	0.00162	0.00292	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—bone cancer	0.00161	0.0029	CcSEcCtD
Fosaprepitant—Weight decreased—Epirubicin—bone cancer	0.00161	0.00289	CcSEcCtD
Fosaprepitant—Infestation NOS—Epirubicin—bone cancer	0.00158	0.00285	CcSEcCtD
Fosaprepitant—Infestation—Epirubicin—bone cancer	0.00158	0.00285	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00157	0.00282	CcSEcCtD
Fosaprepitant—Body temperature increased—Cisplatin—bone cancer	0.00155	0.0028	CcSEcCtD
Fosaprepitant—Stomatitis—Epirubicin—bone cancer	0.00154	0.00278	CcSEcCtD
Fosaprepitant—Conjunctivitis—Epirubicin—bone cancer	0.00154	0.00277	CcSEcCtD
Fosaprepitant—Urinary tract infection—Epirubicin—bone cancer	0.00154	0.00277	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—bone cancer	0.00154	0.00276	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—bone cancer	0.00152	0.00273	CcSEcCtD
Fosaprepitant—Haematuria—Epirubicin—bone cancer	0.00151	0.00272	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—bone cancer	0.0015	0.0027	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—bone cancer	0.0015	0.0027	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—bone cancer	0.00149	0.00268	CcSEcCtD
Fosaprepitant—Weight decreased—Doxorubicin—bone cancer	0.00149	0.00267	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—bone cancer	0.00147	0.00264	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—bone cancer	0.00147	0.00264	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00145	0.00261	CcSEcCtD
Fosaprepitant—Hypersensitivity—Cisplatin—bone cancer	0.00145	0.00261	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—bone cancer	0.00145	0.0026	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—bone cancer	0.00144	0.00258	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—bone cancer	0.00143	0.00257	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—bone cancer	0.00142	0.00256	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—bone cancer	0.00142	0.00256	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—bone cancer	0.00142	0.00255	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—bone cancer	0.00142	0.00255	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—bone cancer	0.00141	0.00254	CcSEcCtD
Fosaprepitant—Asthenia—Cisplatin—bone cancer	0.00141	0.00254	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—bone cancer	0.00141	0.00254	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—bone cancer	0.0014	0.00253	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—bone cancer	0.0014	0.00251	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—bone cancer	0.0014	0.00251	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—bone cancer	0.00139	0.00251	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—bone cancer	0.00138	0.00248	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—bone cancer	0.00137	0.00247	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—bone cancer	0.00137	0.00246	CcSEcCtD
Fosaprepitant—Diarrhoea—Cisplatin—bone cancer	0.00135	0.00242	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—bone cancer	0.00134	0.00242	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—bone cancer	0.00134	0.00241	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—bone cancer	0.00133	0.00239	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—bone cancer	0.00133	0.00239	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—bone cancer	0.00133	0.00238	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—bone cancer	0.00132	0.00238	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—bone cancer	0.00132	0.00238	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—bone cancer	0.00132	0.00237	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—bone cancer	0.00132	0.00237	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—bone cancer	0.00131	0.00235	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—bone cancer	0.0013	0.00234	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—bone cancer	0.00129	0.00233	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—bone cancer	0.00129	0.00233	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—bone cancer	0.00129	0.00232	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—bone cancer	0.00129	0.00232	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—bone cancer	0.00128	0.00231	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—bone cancer	0.00128	0.00231	CcSEcCtD
Fosaprepitant—Vomiting—Cisplatin—bone cancer	0.00125	0.00225	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—bone cancer	0.00125	0.00224	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—bone cancer	0.00124	0.00224	CcSEcCtD
Fosaprepitant—Rash—Cisplatin—bone cancer	0.00124	0.00223	CcSEcCtD
Fosaprepitant—Dermatitis—Cisplatin—bone cancer	0.00124	0.00223	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—bone cancer	0.00124	0.00223	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—bone cancer	0.00124	0.00223	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—bone cancer	0.00123	0.00221	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—bone cancer	0.00123	0.00221	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—bone cancer	0.00123	0.00221	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—bone cancer	0.00122	0.0022	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—bone cancer	0.00122	0.0022	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—bone cancer	0.00122	0.0022	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—bone cancer	0.00122	0.00219	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—bone cancer	0.00121	0.00218	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—bone cancer	0.00119	0.00215	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—bone cancer	0.00119	0.00215	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—bone cancer	0.00119	0.00214	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—bone cancer	0.00119	0.00214	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—bone cancer	0.00119	0.00213	CcSEcCtD
Fosaprepitant—Nausea—Cisplatin—bone cancer	0.00117	0.0021	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—bone cancer	0.00115	0.00208	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—bone cancer	0.00115	0.00207	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—bone cancer	0.00115	0.00207	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—bone cancer	0.00114	0.00206	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—bone cancer	0.00114	0.00206	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—bone cancer	0.00114	0.00206	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—bone cancer	0.00113	0.00203	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—bone cancer	0.00113	0.00203	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—bone cancer	0.00112	0.00202	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00112	0.00201	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—bone cancer	0.00112	0.00201	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—bone cancer	0.00111	0.002	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—bone cancer	0.00111	0.002	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—bone cancer	0.0011	0.00198	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—bone cancer	0.00109	0.00197	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—bone cancer	0.00109	0.00196	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—bone cancer	0.00108	0.00194	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—bone cancer	0.00108	0.00194	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—bone cancer	0.00107	0.00193	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—bone cancer	0.00107	0.00192	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—bone cancer	0.00106	0.00191	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—bone cancer	0.00106	0.0019	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—bone cancer	0.00106	0.0019	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—bone cancer	0.00105	0.0019	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—bone cancer	0.00105	0.00189	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—bone cancer	0.00105	0.00189	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00105	0.00188	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—bone cancer	0.00104	0.00188	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—bone cancer	0.00104	0.00187	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—bone cancer	0.00103	0.00186	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—bone cancer	0.00103	0.00185	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—bone cancer	0.00103	0.00185	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—bone cancer	0.00101	0.00182	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—bone cancer	0.00101	0.00182	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—bone cancer	0.00101	0.00182	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—bone cancer	0.00101	0.00181	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—bone cancer	0.00101	0.00181	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—bone cancer	0.001	0.00181	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—bone cancer	0.000999	0.0018	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—bone cancer	0.000994	0.00179	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—bone cancer	0.00099	0.00178	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—bone cancer	0.000988	0.00178	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—bone cancer	0.000981	0.00177	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—bone cancer	0.000976	0.00176	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—bone cancer	0.000976	0.00176	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—bone cancer	0.000975	0.00175	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—bone cancer	0.000971	0.00175	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000968	0.00174	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—bone cancer	0.000963	0.00173	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—bone cancer	0.000962	0.00173	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—bone cancer	0.000959	0.00173	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—bone cancer	0.000953	0.00172	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—bone cancer	0.00095	0.00171	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—bone cancer	0.000944	0.0017	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—bone cancer	0.000938	0.00169	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—bone cancer	0.000934	0.00168	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—bone cancer	0.000934	0.00168	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—bone cancer	0.000932	0.00168	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—bone cancer	0.00093	0.00167	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—bone cancer	0.000928	0.00167	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—bone cancer	0.000923	0.00166	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—bone cancer	0.000919	0.00165	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—bone cancer	0.000916	0.00165	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—bone cancer	0.000913	0.00164	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—bone cancer	0.000908	0.00163	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—bone cancer	0.000903	0.00163	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—bone cancer	0.0009	0.00162	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—bone cancer	0.000898	0.00162	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—bone cancer	0.000889	0.0016	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—bone cancer	0.000889	0.0016	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—bone cancer	0.000882	0.00159	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—bone cancer	0.000878	0.00158	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—bone cancer	0.000873	0.00157	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—bone cancer	0.000872	0.00157	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—bone cancer	0.000871	0.00157	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—bone cancer	0.000864	0.00155	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—bone cancer	0.000864	0.00155	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—bone cancer	0.000857	0.00154	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—bone cancer	0.000853	0.00153	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—bone cancer	0.000853	0.00153	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—bone cancer	0.000845	0.00152	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—bone cancer	0.000833	0.0015	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—bone cancer	0.000832	0.0015	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—bone cancer	0.000831	0.00149	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—bone cancer	0.000826	0.00149	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—bone cancer	0.000822	0.00148	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—bone cancer	0.000812	0.00146	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000807	0.00145	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—bone cancer	0.000806	0.00145	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—bone cancer	0.000802	0.00144	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—bone cancer	0.000799	0.00144	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—bone cancer	0.000799	0.00144	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—bone cancer	0.000798	0.00144	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—bone cancer	0.000798	0.00144	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—bone cancer	0.000795	0.00143	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—bone cancer	0.000774	0.00139	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—bone cancer	0.00077	0.00139	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—bone cancer	0.000764	0.00137	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—bone cancer	0.000763	0.00137	CcSEcCtD
Fosaprepitant—Hypersensitivity—Epirubicin—bone cancer	0.000744	0.00134	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—bone cancer	0.000742	0.00134	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—bone cancer	0.000739	0.00133	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—bone cancer	0.000739	0.00133	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—bone cancer	0.000738	0.00133	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—bone cancer	0.000725	0.0013	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—bone cancer	0.000714	0.00129	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—bone cancer	0.000714	0.00128	CcSEcCtD
Fosaprepitant—Diarrhoea—Epirubicin—bone cancer	0.000691	0.00124	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—bone cancer	0.000688	0.00124	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—bone cancer	0.000686	0.00123	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—bone cancer	0.00068	0.00122	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—bone cancer	0.00068	0.00122	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—bone cancer	0.000676	0.00122	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—bone cancer	0.00067	0.00121	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—bone cancer	0.000668	0.0012	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—bone cancer	0.000661	0.00119	CcSEcCtD
Fosaprepitant—Vomiting—Epirubicin—bone cancer	0.000642	0.00116	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—bone cancer	0.000641	0.00115	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—bone cancer	0.000639	0.00115	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—bone cancer	0.000637	0.00115	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—bone cancer	0.000636	0.00114	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—bone cancer	0.000633	0.00114	CcSEcCtD
Fosaprepitant—Dizziness—Doxorubicin—bone cancer	0.000618	0.00111	CcSEcCtD
Fosaprepitant—Nausea—Epirubicin—bone cancer	0.0006	0.00108	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—bone cancer	0.000594	0.00107	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—bone cancer	0.000589	0.00106	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—bone cancer	0.000589	0.00106	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—bone cancer	0.000585	0.00105	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—bone cancer	0.000555	0.000999	CcSEcCtD
